EGFR and non-small cell lung carcinoma: <h4>Objective</h4>To report a well-documented case of cytokine release syndrome (CRS) following the first cycle of amivantamab combined with chemotherapy in a patient with osimertinib-resistant EGFR-mutant non-small cell lung cancer (NSCLC), highlighting its diagnosis, management, and association with a rapid antitumor response.<h4>Case summary</h4>A 72-year-old man with metastatic lung adenocarcinoma (epidermal growth factor receptor (EGFR) exon 19 del) progressing on osimertinib initiated treatment with amivantamab, pemetrexed, and carboplatin.